行情

NVUS

NVUS

Novus
NASDAQ

实时行情|Nasdaq Last Sale

0.6919
+0.0019
+0.28%
休市 16:00 01/17 EST
开盘
0.6823
昨收
0.6900
最高
0.7480
最低
0.6330
成交量
21.65万
成交额
--
52周最高
5.21
52周最低
0.4000
市值
897.73万
市盈率(TTM)
-0.4395
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

NVUS 新闻

  • 隔夜要闻:美股周一休市 财报季进入白热化阶段在即
  • 新浪美股.5小时前
  • 供应充足预期冲淡利比亚局势影响 油价微涨
  • 新浪美股.6小时前
  • 日本央行料将按兵不动 投行普遍认为宽松空间不大
  • FX168.7小时前
  • "数字税"休战:美法同意将潜在关税战推迟到年底
  • 新浪美股.7小时前

更多

所属板块

制药
+0.13%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

NVUS 简况

Novus Therapeutics, Inc., formerly Tokai Pharmaceuticals, Inc., is a pharmaceutical company. The Company is focused on the acquisition, development, and commercialization of ear, nose, and throat products. It has two platforms: OP-01 Foam Platform and OP-02 Surfactant Program. OP-01 is developed with the intent to be used as a delivery vehicle for drugs treating ears, as well as the nasal and sinus cavities. OP-01 is currently being developed as an improved treatment option for acute otitis externa. OP-02 is a daily nasal spray that is designed to improve and maintain a healthy middle ear. OP-02 is being developed as a potential treatment option for patients with otitis media and Eustachian tube dysfunction. OP-02 is a combination drug product, which comprises two components: surfactant dipalmitoylphosphatidylcholine and a spreading agent cholesteryl palmitate. The product is sprayed through the nostrils toward the opening of the Eustachian tube at the back of the nasal cavity.
展开

Webull提供Novus Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。